MIDD can ease pediatric & rare disease drug loss in Japan
Certara tackles pediatric cancer and rare disease drug loss in Japan by advocating MIDD, which…
CertaraJuly 8, 2025
Accelerating Oncology Drug FDA RTOR Submission with Project Management Services
Discover how Certara’s dedicated project management and pharmacometric support helped an emerging biotech company fast-track…
CertaraJuly 2, 2025
A Practical Guide to Creating Effective Budget Impact Models
BaseCase empowers market access, medical, and sales teams to effectively engage decision-makers by translating complex…
CertaraJuly 1, 2025
The Reference-scaled Average Bioequivalence (RSABE) Approach
We examine the Reference-scaled Average Bioequivalence (RSABE) approach for generic drug development and how it…
CertaraJuly 1, 2025
The Medicine Maker: The Biosimulation Generation
The article, The Biosimulation Generation, explores the transformative potential of biosimulation in pharmaceutical R&D as…
Danielle PillsburyJuly 1, 2025
5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address
June 30, 2025 Drug development is increasingly defined by its complexity. Teams must navigate rising…
CertaraJune 30, 2025
